SK Biopharmaceuticals Co., Ltd. (KRX:326030)
126,500
+200 (0.16%)
At close: Nov 21, 2025
SK Biopharmaceuticals Revenue
SK Biopharmaceuticals had revenue of 191.73B KRW in the quarter ending September 30, 2025, with 40.35% growth. This brings the company's revenue in the last twelve months to 675.41B, up 32.09% year-over-year. In the year 2024, SK Biopharmaceuticals had annual revenue of 547.60B with 54.30% growth.
Revenue (ttm)
675.41B
Revenue Growth
+32.09%
P/S Ratio
14.67
Revenue / Employee
2.75B
Employees
246
Market Cap
9.91T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 547.60B | 192.70B | 54.30% |
| Dec 31, 2023 | 354.89B | 108.71B | 44.16% |
| Dec 31, 2022 | 246.18B | -172.47B | -41.20% |
| Dec 31, 2021 | 418.64B | 392.65B | 1,510.23% |
| Dec 31, 2020 | 26.00B | -97.85B | -79.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |